Cargando…

The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors

Effective cancer therapeutics for brain tumors must be able to cross the blood-brain barrier (BBB) to reach the tumor in adequate quantities and overcome the resistance conferred by the local tumor microenvironment. Clinically approved chemotherapeutic agents have been investigated for brain neoplas...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Elizabeth, Choi, Peter J., Denny, William A., Jose, Jiney, Dragunow, Mike, Park, Thomas I.-H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204086/
https://www.ncbi.nlm.nih.gov/pubmed/34141613
http://dx.doi.org/10.3389/fonc.2021.654921
_version_ 1783708285042425856
author Cooper, Elizabeth
Choi, Peter J.
Denny, William A.
Jose, Jiney
Dragunow, Mike
Park, Thomas I.-H.
author_facet Cooper, Elizabeth
Choi, Peter J.
Denny, William A.
Jose, Jiney
Dragunow, Mike
Park, Thomas I.-H.
author_sort Cooper, Elizabeth
collection PubMed
description Effective cancer therapeutics for brain tumors must be able to cross the blood-brain barrier (BBB) to reach the tumor in adequate quantities and overcome the resistance conferred by the local tumor microenvironment. Clinically approved chemotherapeutic agents have been investigated for brain neoplasms, but despite their effectiveness in peripheral cancers, failed to show therapeutic success in brain tumors. This is largely due to their poor bioavailability and specificity towards brain tumors. A targeted delivery system might improve the efficacy of the candidate compounds by increasing the retention time in the tumor tissue, and minimizing the numerous side effects associated with the non-specific distribution of the chemotherapy agent. Heptamethine cyanine dyes (HMCDs) are a class of near-infrared fluorescence (NIRF) compounds that have recently emerged as promising agents for drug delivery. Initially explored for their use in imaging and monitoring neoplasms, their tumor-targeting properties have recently been investigated for their use as drug carrier systems. This review will explore the recent developments in the tumour-targeting properties of a specific group of NIRF cyanine dyes and the preclinical evidence for their potential as drug-delivery systems in the treatment of primary and metastatic brain tumors.
format Online
Article
Text
id pubmed-8204086
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82040862021-06-16 The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors Cooper, Elizabeth Choi, Peter J. Denny, William A. Jose, Jiney Dragunow, Mike Park, Thomas I.-H. Front Oncol Oncology Effective cancer therapeutics for brain tumors must be able to cross the blood-brain barrier (BBB) to reach the tumor in adequate quantities and overcome the resistance conferred by the local tumor microenvironment. Clinically approved chemotherapeutic agents have been investigated for brain neoplasms, but despite their effectiveness in peripheral cancers, failed to show therapeutic success in brain tumors. This is largely due to their poor bioavailability and specificity towards brain tumors. A targeted delivery system might improve the efficacy of the candidate compounds by increasing the retention time in the tumor tissue, and minimizing the numerous side effects associated with the non-specific distribution of the chemotherapy agent. Heptamethine cyanine dyes (HMCDs) are a class of near-infrared fluorescence (NIRF) compounds that have recently emerged as promising agents for drug delivery. Initially explored for their use in imaging and monitoring neoplasms, their tumor-targeting properties have recently been investigated for their use as drug carrier systems. This review will explore the recent developments in the tumour-targeting properties of a specific group of NIRF cyanine dyes and the preclinical evidence for their potential as drug-delivery systems in the treatment of primary and metastatic brain tumors. Frontiers Media S.A. 2021-06-01 /pmc/articles/PMC8204086/ /pubmed/34141613 http://dx.doi.org/10.3389/fonc.2021.654921 Text en Copyright © 2021 Cooper, Choi, Denny, Jose, Dragunow and Park https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cooper, Elizabeth
Choi, Peter J.
Denny, William A.
Jose, Jiney
Dragunow, Mike
Park, Thomas I.-H.
The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors
title The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors
title_full The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors
title_fullStr The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors
title_full_unstemmed The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors
title_short The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors
title_sort use of heptamethine cyanine dyes as drug-conjugate systems in the treatment of primary and metastatic brain tumors
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204086/
https://www.ncbi.nlm.nih.gov/pubmed/34141613
http://dx.doi.org/10.3389/fonc.2021.654921
work_keys_str_mv AT cooperelizabeth theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors
AT choipeterj theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors
AT dennywilliama theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors
AT josejiney theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors
AT dragunowmike theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors
AT parkthomasih theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors
AT cooperelizabeth useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors
AT choipeterj useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors
AT dennywilliama useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors
AT josejiney useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors
AT dragunowmike useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors
AT parkthomasih useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors